Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication

Diabetes Obesity and Metabolism(2022)10.1111/dom.14724Source: DataRank Database

A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication is a research paper published in Diabetes Obesity and Metabolism (2022). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.40)OA: greenTopics (44)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Rafael Caiado‐Vencio ORCID,Leonardo Caixeta ORCID,Małgorzata Masierek ORCID,Wojciech Młynarski ORCID,Józef Drzewoski ORCID

Live enrichment

PubMed:35441466 OpenAlex:https://openalex.org/W4224260950

National Institutes of Health

Grant: 1K23DK123392-01A1

Determination of Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Recent-Onset Type 1 Diabetes

FWCI

0.40

Citation Percentile

0.6%

Citation Trend

2023

2025

greenLicense: Wiley Online Library User Agreement

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10146588/pdf/nihms-1890170.pdf

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14724

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/dom.14724

publisherhttps://dom-pubs.pericles-prod.literatumonline.com/doi/pdf/10.1111/dom.14724

Fields of Study

Diabetes Management and ResearchBiosimilars and Bioanalytical MethodsProtein purification and stability03 medical and health sciences0302 clinical medicine

MeSH Terms

Diabetes Mellitus, Type 1Double-Blind MethodGlucoseHumansHypoglycemic AgentsInsulinInsulin, IsophaneTherapeutic EquivalencyGlucose Clamp TechniqueCross-Over StudiesBiosimilar PharmaceuticalsInsulin, Regular, Human

Keywords

BioequivalenceMedicineCrossover studyPharmacodynamicsPharmacokineticsInsulinConfidence intervalType 1 diabetesType 2 diabetesDiabetes mellitusInternal medicineArea under the curveDosePharmacologyEndocrinologyPlaceboCross-Over StudiesInsulin, IsophaneDiabetes Mellitus, Type 1GlucoseDouble-Blind MethodTherapeutic EquivalencyInsulin, Regular, HumanGlucose Clamp TechniqueHumansHypoglycemic AgentsBiosimilar Pharmaceuticals

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justice